Figure 2

Schematic presentation of the process employed to identify peptoids that bind to antibodies present at higher levels in Alzheimer’s disease patients. Serum samples were hybridized to an array of thousands of eight-mer peptoids spotted covalently onto chemically modified glass microscope slides. After washing and addition of a fluorescent-labeled secondary antibody, the signals were read at each spot. Peptoid spots that consistently captured at least three times more IgG antibodies from the serum of the Alzheimer’s disease patients than that from controls were sequenced by mass spectrometry to identify the structure.